


QUILT-88: NANT Pancreatic Cancer Vaccine in 3rd, 4th, & 5th Line Advanced Disease

Targeting PD-L1 With Chimeric Antigen Receptor Modified NK Cells Induces Tumor Control and Reduction of PD-L1 High Immune Populations

Engineered killer immune cells target tumours and their immunosuppressive allies
